3 ms·
> You can make improvements to the product, and patent those changes Yes, that’s exactly what Feldman & the article said. The patent applications for “new” dru
by dahart 8y ago
> You can make improvements to the product, and patent those changes
Yes, that’s exactly what Feldman & the article said. The patent applications for “new” drugs use an existing base drug, modify it in some way that can be called an improvement, and get the drug protected for a 2nd or 3rd time. The point is that the modification is not improving the drug itself the majority of the time, but some secondary component or the delivery mechanism. Do you have any actual evidence that contradicts the idea of evergreening? Here’s a direct link to Feldman’s research: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3061567 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3061567
> As a threshold matter, no scientist or engineer would say that incremental improvements don’t count as “innovation”.
“Innovation” in this context is referring to research to create brand new drugs, which is what big pharma cites as their reason for needing to charge high prices, and what the patent system requires when filing protections on new drugs. The point is that, despite minor innovations to drugs, they’re not meeting the innovation level that both the companies themselves are claiming they have, and that should be required for patents.
> If the change doesn’t actually result in a therapeutic benefit, then doctors shouldn’t prescribe the new drug over the generic. For various reasons, doctors have little incentive to do that.
Yes, exactly. In theory, generics should easily win when they’re available due to their lower cost. What you’re gently glossing over in your comment is the active incentives big pharma is injecting into the system to secure a place for their higher cost drugs. Some doctors & hospitals & insurance companies are being paid extra, directly and indirectly, to not offer generics.
> But the newer iterations are at least a little bit better, and who wants to give their kid with Type-1 diabetes anything but the latest and greatest version?
Well, that actually depends on the free flow of information. If the new drug is a combination of two existing drugs, you can call it “better”, but in reality it may be 10x the price and no actual therapeutic benefit compared to what was already there. This exists in many drugs, for example existing pain killers being combined with existing anti-nausea drugs, and then a high premium is charged for the combo. The point is that the high premium is completely unnecessary to the patient’s relief.